Individualized management of advanced bladder cancer: Where do we stand?

Area of Science:

• Uro-oncology
• Medical oncology
• Translational research

Background:

• Management of advanced urothelial carcinoma has seen limited progress over two decades.
• Patient comorbidities often contraindicate standard cisplatin-based chemotherapy.
• There is a critical need for individualized treatment strategies and novel therapies.

Purpose of the Study:

• To review current challenges in managing locally advanced and metastatic urothelial carcinoma.
• To highlight recent molecular discoveries for personalized treatment approaches.

Main Methods:

• Literature review of recent advances in urothelial carcinoma management.
• Analysis of molecular aberrations and their therapeutic implications.

Main Results:

• Limited progress in standard treatment protocols for advanced urothelial cancer.
• Identification of molecular targets offers potential for personalized medicine.
• Comorbidities necessitate alternative therapeutic strategies.

Conclusions:

• Personalized therapeutic decision-making is crucial for advanced urothelial carcinoma.
• Molecular profiling can guide the development of more effective, individualized treatments.
• Further research into targeted therapies is essential for improving patient outcomes.